Speech Pattern Evaluation and Analysis for Knowledge of AD (SPEAK-AD)

University of Wisconsin (UW) logo

University of Wisconsin (UW)

Status

Not yet enrolling

Conditions

Wisconsin Alzheimer's Disease Research Center
Wisconsin Registry for Alzheimer's Prevention

Treatments

Other: TalkTracker

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT06230783
Protocol Version 12/15/2023 (Other Identifier)
SMPH/MEDICINE/GER-AD DEV (Other Identifier)
A534255 (Other Identifier)
1R01AG082052-01 (U.S. NIH Grant/Contract)
2023-1740

Details and patient eligibility

About

The goal of this observational study is to validate changes in speech as a measure of cognition in individuals at increased risk of Alzheimer's disease and related dementias (ADRD). This study aims to clarify how speech may be affected by Alzheimer's disease. Participants will complete speech collection sessions and a survey at home using an iPad. Participants can expect to be in the study for 3 years.

Full description

Digital technology, including recorded speech, has the capability of providing a wealth of information about early changes to cognition and communication associated with developing Alzheimer's disease pathology, with the potential for highly accessible, yet low-burden measurement. In this project, researchers will recruit a subset of participants from two longitudinal, observational cohort studies enriched for individuals at risk for or living with Alzheimer's disease to record their speech at home with a mobile device, longitudinally. Our interdisciplinary team will then validate digital markers across all stages of Alzheimer's Disease and Related Dementias (ADRD), including the prodromal phase, and can enhance sensitivity and specificity of speech metrics while contributing valuable information about remote, noninvasive, and accessible assessment and disease monitoring.

Enrollment

150 estimated patients

Sex

All

Ages

40 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Must be enrolled in the Wisconsin Alzheimer's Disease Research Center (W-ADRC) Clinical Core or IMPACT studies, or in the Wisconsin Registry for Alzheimer's Prevention (WRAP)
  • Cognitively unimpaired or have a diagnosis of Mild Cognitive Impairment (MCI)
  • Ages 40-80 years
  • Have provided W-ADRC or WRAP with blood plasma Alzheimer's Disease

Exclusion criteria

  • Not actively enrolled in W-ADRC or WRAP
  • Diagnosis of dementia
  • Impaired capacity or unwilling to consent
  • Have not completed a main W-ADRC/WRAP study visit within approximately 6 months of enrollment
  • Major neurological conditions
  • Speech disorders

Trial contacts and locations

1

Loading...

Central trial contact

Leah K Sanson-Miles

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems